Discover
EPIX
ESSA Pharma Inc.
0.20
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | ||
| 1y |
0.20
day range
0.20
52 week range
| Open | 0.20 | Prev Close | 0.20 | Low | 0.20 | High | 0.20 | Mkt Cap | N/A |
| Vol | 5.82M | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -3.26 |
| Beta | 1.84 | Short Ratio | 0.32 | Inst. Own | 81.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 9.19 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-02-11 | 2024-12 | -0.18 | N/A | N/A | N/A |
| 2024-12-17 | 2024-09 | -0.19 | -0.14 | 0.05 | 26.32% |
| 2024-08-05 | 2024-06 | -0.26 | -0.16 | 0.1 | 38.46% |
| 2024-05-14 | 2024-03 | -0.19 | -0.2 | -0.01 | -5.26% |
| 2024-02-13 | 2023-12 | -0.17 | -0.14 | 0.03 | 17.65% |
| 2023-12-12 | 2023-09 | -0.22 | -0.12 | 0.1 | 45.45% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-04 | Piper Sandler | Downgrade | Overweight | Neutral |
| 2024-11-04 | Oppenheimer | Downgrade | Outperform | Perform |
| 2024-11-01 | Jones Trading | Downgrade | Buy | Hold |
| 2024-05-16 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2023-12-13 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2023-08-09 | Oppenheimer | Upgrade | Outperform | Outperform |
Profile
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | BVF Inc. | 8.75M | 14.26M | 19.71% |
| 2024-09-29 | Bellevue Group AG | 7.88M | 12.84M | 17.75% |
| 2024-09-29 | Soleus Capital Management, L.P. | 4.29M | 6.99M | 9.66% |
| 2024-09-29 | Morgan Stanley | 4.18M | 6.82M | 9.42% |
| 2024-09-29 | RTW Investments LP | 3.26M | 5.32M | 7.35% |
| 2024-09-29 | Pfm Health Sciences, Lp | 2.74M | 4.47M | 6.18% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Avantis U.S. Small Cap Equity ETF | 46.65K | 76.04K | 0.11% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 26.86K | 43.78K | 0.06% |
| 2024-09-29 | North Square Inv Tr-North Square Kennedy MicroCap Fund | 5.85K | 9.54K | 0.01% |
Dividend
| Dividend | Date |
|---|---|
| 1.69 | 2025-08-25 |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2018-04-25 |